scholarly journals Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations

2021 ◽  
Vol 68 (S4) ◽  
Author(s):  
Ewa Bien ◽  
Jelena Roganovic ◽  
Malgorzata A. Krawczyk ◽  
Jan Godzinski ◽  
Daniel Orbach ◽  
...  
Keyword(s):  
Therapeutic Recommendations

Therapeutic recommendations in hypothyroidism

Farmacist ro ◽  
2020 ◽  
Vol 5 (196) ◽  
pp. 20
Author(s):  
Nicoleta Mirela Blebea ◽  
Laura Bucur
Keyword(s):  
Therapeutic Recommendations

A Critical Approach of Guideline Therapeutic Recommendations for NAFLD

2018 ◽  
Vol 16 (3) ◽  
pp. 228-238 ◽  
Author(s):  
Dragan B. Djordjevic ◽  
Marija Zdravkovic ◽  
Aleksandar Nagorni ◽  
Athanasios Manolis ◽  
Costas Tsioufis ◽  
...  
Keyword(s):  
Critical Approach ◽  
Therapeutic Recommendations

scholarly journals COVID‐19 Vaccine‐associated Immune Thrombosis and Thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome

2021 ◽  
Author(s):  
Massimo Franchini ◽  
Giancarlo Maria Liumbruno ◽  
Mario Pezzo
Keyword(s):  
Therapeutic Recommendations

scholarly journals Adrenocortical tumours in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

2021 ◽  
Vol 68 (S4) ◽  
Author(s):  
Calogero Virgone ◽  
Jelena Roganovic ◽  
Peter Vorwerk ◽  
Antje Redlich ◽  
Dominik T. Schneider ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Adrenocortical Tumours ◽  
Therapeutic Recommendations

Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

2008 ◽  
Vol 255 (10) ◽  
pp. 1449-1463 ◽  
Author(s):  
◽  
H. Wiendl ◽  
K. V. Toyka ◽  
P. Rieckmann ◽  
R. Gold ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Recommendations

scholarly journals Do Guidelines for the Diagnosis and Monitoring of Diabetes Mellitus Fulfill the Criteria of Evidence-Based Guideline Development?

2008 ◽  
Vol 54 (11) ◽  
pp. 1872-1882 ◽  
Author(s):  
Eva Nagy ◽  
Joseph Watine ◽  
Peter S Bunting ◽  
Rita Onody ◽  
Wytze P Oosterhuis ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Methodological Quality ◽  
Guideline Development ◽  
Evidence Based ◽  
Test Results ◽  
Time Period ◽  
Therapeutic Guidelines ◽  
Therapeutic Recommendations ◽  
Evidence Based Guideline

Abstract Background: Although the methodological quality of therapeutic guidelines (GLs) has been criticized, little is known regarding the quality of GLs that make diagnostic recommendations. Therefore, we assessed the methodological quality of GLs providing diagnostic recommendations for managing diabetes mellitus (DM) and explored several reasons for differences in quality across these GLs. Methods: After systematic searches of published and electronic resources dated between 1999 and 2007, 26 DM GLs, published in English, were selected and scored for methodological quality using the AGREE Instrument. Subgroup analyses were performed based on the source, scope, length, origin, and date and type of publication of GLs. Using a checklist, we collected laboratory-specific items within GLs thought to be important for interpretation of test results. Results: The 26 diagnostic GLs had significant shortcomings in methodological quality according to the AGREE criteria. GLs from agencies that had clear procedures for GL development, were longer than 50 pages, or were published in electronic databases were of higher quality. Diagnostic GLs contained more preanalytical or analytical information than combined (i.e., diagnostic and therapeutic) recommendations, but the overall quality was not significantly different. The quality of GLs did not show much improvement over the time period investigated. Conclusions: The methodological shortcomings of diagnostic GLs in DM raise questions regarding the validity of recommendations in these documents that may affect their implementation in practice. Our results suggest the need for standardization of GL terminology and for higher-quality, systematically developed recommendations based on explicit guideline development and reporting standards in laboratory medicine.

scholarly journals Chronic venous insufficiency – epidemiology, classification and clinical picture. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I

2018 ◽  
Vol 105 (4) ◽  
pp. 473-485
Author(s):  
Joanna Narbutt ◽  
Monika Bowszyc-Dmochowska ◽  
Monika Kapińska-Mrowiecka ◽  
Andrzej Kaszuba ◽  
Dorota Krasowska ◽  
...  
Keyword(s):  
Clinical Picture ◽  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Therapeutic Recommendations

AIDS-Related Malignancies: State of the Art and Therapeutic Challenges

2008 ◽  
Vol 26 (29) ◽  
pp. 4834-4842 ◽  
Author(s):  
Jean-Philippe Spano ◽  
Dominique Costagliola ◽  
Christine Katlama ◽  
Nicolas Mounier ◽  
Eric Oksenhendler ◽  
...  
Keyword(s):  
Patient Outcomes ◽  
Hodgkin’S Lymphoma ◽  
Advanced Disease ◽  
State Of The Art ◽  
Hodgkin's Lymphoma ◽  
Increased Risk ◽  
Therapeutic Recommendations ◽  
The Subject ◽  
The Impact ◽  
Related Mortality

Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era. Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non–AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes. Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others. Antiretroviral agents have a propensity for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system. Because many antineoplastic drugs are also metabolized by the CYP system, coadministration with cART could result in either drug accumulation with increased toxicity, or decreased efficacy of one or both classes of drugs. Further research delineating the combined safety and pharmacokinetics of antiretrovirals and antineoplastic therapy is necessary. Special considerations of these AIDS-related and non–AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

Sign in / Sign up

Export Citation Format

Share Document